TECON BIOLOGY Co.LTD (SHE:002100)
China · Delayed Price · Currency is CNY 6.92
-0.10 (-1.42%)
At close: Feb 13, 2026
TECON BIOLOGY Co.LTD Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 17,637 | 17,114 | 18,973 | 16,958 | 15,663 | 11,960 |
Other Revenue | 62.23 | 62.23 | 52.75 | 31.07 | 47.43 | 26.81 |
| 17,699 | 17,176 | 19,026 | 16,989 | 15,711 | 11,987 | |
Revenue Growth (YoY) | 1.68% | -9.72% | 11.99% | 8.14% | 31.07% | 60.33% |
Cost of Revenue | 15,715 | 15,103 | 18,965 | 15,375 | 14,595 | 8,592 |
Gross Profit | 1,985 | 2,073 | 61.29 | 1,615 | 1,116 | 3,395 |
Selling, General & Admin | 956.18 | 989.66 | 1,030 | 971.45 | 1,340 | 1,276 |
Research & Development | 109.17 | 194.2 | 252.85 | 176.38 | 167.89 | 101.36 |
Other Operating Expenses | 56.16 | 45.81 | 46.8 | 38.72 | 38.33 | 34.64 |
Operating Expenses | 1,155 | 1,254 | 1,347 | 1,237 | 1,570 | 1,423 |
Operating Income | 829.74 | 818.1 | -1,286 | 377.63 | -454.1 | 1,971 |
Interest Expense | -153.9 | -178.94 | -245.54 | -248.55 | -206.09 | -196.3 |
Interest & Investment Income | 28.93 | 38.64 | 60.94 | 64.94 | 46.99 | 49.4 |
Currency Exchange Gain (Loss) | -0 | -0 | - | - | - | - |
Other Non Operating Income (Expenses) | -84.96 | -99.29 | -39.41 | -5.87 | -1.9 | -2.04 |
EBT Excluding Unusual Items | 619.8 | 578.52 | -1,510 | 188.14 | -615.1 | 1,823 |
Impairment of Goodwill | -12.66 | -12.66 | -9.58 | - | - | - |
Gain (Loss) on Sale of Investments | -10.86 | -1.87 | -0 | 0.94 | - | -0.78 |
Gain (Loss) on Sale of Assets | 2.04 | 4.5 | 3.9 | 0.23 | -36.72 | -60.29 |
Asset Writedown | -128.73 | -28.91 | -34.12 | -0.06 | -48.63 | - |
Other Unusual Items | 84.62 | 71.23 | 56.63 | 26.79 | 37 | 46.3 |
Pretax Income | 554.22 | 610.81 | -1,493 | 216.03 | -663.45 | 1,808 |
Income Tax Expense | 7.43 | 14.39 | 23.46 | 26.03 | 31.9 | 22.43 |
Earnings From Continuing Operations | 546.79 | 596.42 | -1,516 | 190 | -695.35 | 1,785 |
Minority Interest in Earnings | -95.61 | 8.63 | 153.11 | 90.78 | -7.45 | -64.89 |
Net Income | 451.18 | 605.05 | -1,363 | 280.78 | -702.79 | 1,720 |
Net Income to Common | 451.18 | 605.05 | -1,363 | 280.78 | -702.79 | 1,720 |
Net Income Growth | - | - | - | - | - | 166.94% |
Shares Outstanding (Basic) | 1,370 | 1,375 | 1,350 | 1,337 | 1,098 | 1,069 |
Shares Outstanding (Diluted) | 1,370 | 1,375 | 1,350 | 1,337 | 1,098 | 1,075 |
Shares Change (YoY) | 0.57% | 1.88% | 0.95% | 21.76% | 2.13% | 0.10% |
EPS (Basic) | 0.33 | 0.44 | -1.01 | 0.21 | -0.64 | 1.61 |
EPS (Diluted) | 0.33 | 0.44 | -1.01 | 0.21 | -0.64 | 1.60 |
EPS Growth | - | - | - | - | - | 166.67% |
Free Cash Flow | 1,031 | 535.4 | 750.48 | -1,102 | -219.37 | -1,531 |
Free Cash Flow Per Share | 0.75 | 0.39 | 0.56 | -0.82 | -0.20 | -1.42 |
Dividend Per Share | 0.220 | 0.220 | - | 0.220 | - | 0.460 |
Dividend Growth | - | - | - | - | - | 130.00% |
Gross Margin | 11.21% | 12.07% | 0.32% | 9.50% | 7.11% | 28.32% |
Operating Margin | 4.69% | 4.76% | -6.76% | 2.22% | -2.89% | 16.45% |
Profit Margin | 2.55% | 3.52% | -7.17% | 1.65% | -4.47% | 14.35% |
Free Cash Flow Margin | 5.83% | 3.12% | 3.94% | -6.49% | -1.40% | -12.77% |
EBITDA | 1,464 | 1,525 | -482.87 | 1,091 | 250.85 | 2,420 |
EBITDA Margin | 8.27% | 8.88% | -2.54% | 6.42% | 1.60% | 20.18% |
D&A For EBITDA | 634.64 | 706.76 | 802.92 | 713.19 | 704.95 | 448.11 |
EBIT | 829.74 | 818.1 | -1,286 | 377.63 | -454.1 | 1,971 |
EBIT Margin | 4.69% | 4.76% | -6.76% | 2.22% | -2.89% | 16.45% |
Effective Tax Rate | 1.34% | 2.36% | - | 12.05% | - | 1.24% |
Revenue as Reported | 17,699 | 17,176 | 19,026 | 16,989 | 15,711 | 11,987 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.